Latest News

Kalbe Farma Commemorates World Cancer Day

Debunk the Myths : Between Fact and Myth

Kalbe Farma Commemorates World Cancer Day

Press Release No. 007/KFCP-DIR/PR/II/14

Jakarta, 9 February 2014 – PT Kalbe Farma Tbk (Kalbe) through Kalbe Ethical Customer Care (KECC) and Indonesia Cancer Care Community (ICCC) today commemorates the World Cancer Day.  The World Cancer Day commemoration that is held at Candi Bentar, Putri Duyung Ancol, Jakarta, takes the theme of "Facts and Myths of Cancer". Around five hundred cancer patients, survivors, and observers will be present in the event.  

“Kalbe will always present its commitment on public health in general, and cancer patients in particular. We will always encourage cancer patients to not lose hope and stay productive,” said Johannes Suthya, Deputy Director of PT Kalbe Farma Tbk. ”Kalbe's contribution to cancer patients is also done through the production of cancer medications from Kalbe's Onko factory that was inaugurated on 23 January 2014,” he added.

The main event of the World Cancer Day commemoration which is held on every February 4 is the discussion on the Facts and Myths of Cancer with the speaker Dr. Walta Gautama ST, SpB (K) Onk, Chief of Early Detection of Cancer Division of Dharmais Cancer Hospital and the Secretary General of the Indonesian Oncologic Surgeons Association. The theme is chosen to clarify the myths of cancer that is circulating in the general public and give the facts of the truth behind the myths.

There will also be health-walks around the area, sharing between children and adult cancer patients, performances from Children with Cancer, survivors and patients, Nutrican Healthy Menu Cooking demonstration, and several charity booths to collect funds to be donated to the Cancer Foundation.

There are more than 10 million cancer patients worldwide at present day. The number is expected to rise by 2.4% in 2020 to be 14 million sufferers per year.  It is predicted that there will be 22 million people with cancer and 7 million will die every year due to cancer. Breast cancer, colon cancer, stomach, lung, liver, prostate and cervix cancers are the most common types of cancer.

The threat of cancer in Indonesia is also increasing with the change of lifestyle of the population. According to World Cancer Prevention Organization and World Health Organization, it is predicted to be an increase of cancer by 300 percent by year 2030, and the majority of the case will happen in developing countries, including Indonesia. According to the Department of Health, at present, there is 1 cancer patient in 1,000 people in Indonesia and it is estimated that there will be 200,000 new cancer patients every year.

Kalbe Ethical Customer Care (KECC) at a glance
Kalbe Ethical Customer Care or KECC is a forum dedicated to providing information and education to the public about overall health.

KECC works to increase the awareness and concern of the public for their own health. In addition, the public is also encouraged to always identify the prevention and medication of diseases, especially chronic or degenerative diseases.. In every activity, KECC also perform a variety of checks for the participants such as: bone density check, blood sugar, blood pressure, etc.

Kalbe at a glance
PT Kalbe Farma Tbk (“Kalbe”) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle their reliable and diversed brand portfolio, prescription drugs (Cefspan, Brainact, Broadced, etc); over-the-counter drugs (Woods, Promag, Mixagrip, Komix, Fatigon, etc); nutrition (ChilKid, Prenagen, Diabetasol, etc); and distribution business units. Kalbe currently has more than 20 subsidiaries, 9 production facilities with international standard, and employs more than 15,000 employees and 4,000 sales force and marketing agents, dispersed across more than 65 branches throughout Indonesia. From 1991, Kalbe is listed at Indonesia Stock Exchange (IDX:KLBF).

2226 Rate this article:
No rating

Please login or register to post comments.